Sign in with Google
bullish
BeiGene IPO Preview: Lucrative Lifesavers
625 Views30 Jul 2018 22:02
BeiGene (BGNE US) is set to become the first overseas listed biotech firm to seek a secondary listing in Hong Kong, under the city’s newly revamped...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 9-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Goldlion Holdings (533 HK): An Unexpected HK Arbageddon
- Sinarmas Land (SML SP): Potential Outcomes as IFA Says NOT Fair but Reasonable
- [Japan M&A] Bloomberg Reports Bain MBO on Nissin (9066) May Come Monday - The Implied Price Is Light
- Nissin Corp (9066 JP): A Rumoured Bain-Sponsored MBO?
- Taiwan Dual-Listings Monitor: TSMC Local Short Interest Approaching Highs; ASE Close to Parity
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene01 Oct 2018
- Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome02 Sep 2018
- BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis12 Aug 2018
- Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation22 Jul 2018
x